Interferon-β-1a in relapsing-remitting multiple sclerosis:: effect on hypointense lesion volume on T1 weighted images

被引:24
作者
Gasperini, C
Pozzilli, C
Bastianello, S
Giugni, E
Horsfield, MA
Koudriavtseva, T
Galgani, S
Paolillo, A
Haggiag, S
Millefiorini, E
Fieschi, C
机构
[1] Univ Rome La Sapienza, Dept Neurol Sci, I-00185 Rome, Italy
[2] S Camillo Hosp, Dept Neurol, Rome, Italy
[3] Univ Leicester, Div Med Phys, Leicester LE1 7RH, Leics, England
关键词
multiple sclerosis; relapsing remitting; magnetic resonance imaging; disability; interferon-beta; therapy;
D O I
10.1136/jnnp.67.5.579
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective-Recently, a strong correlation between the increase in hypointense lesion load on T1 weighted spin echo images, and the increase in disability was reported. Although the effect of interferon-beta has been demonstrated both in reducing exacerbation rate, frequency of enhancing lesions, and accumulation of disease burden on T2 weighted images, the impact on the accumulation of hypointense lesions has not yet been evaluated. The aims of the present study were: (a) to assess for the first time the effect of interferon-beta-1a on T1 weighted MRI hypointense lesion volume; and (b) to evaluate the relation between changes on hypointense, hyperintense, and enhancing lesion volume before and during interferon-beta-1a treatment in relapsing-remitting multiple sclerosis. Methods-After a baseline scan and 6 month pretreatment period, 67 patients with relapsing-remitting multiple sclerosis were treated with interferon-beta-1a by subcutaneous injection three times a week during a 12 month treatment period. All patients had MRI every month during the 6 month pretreatment period and for the first 9 months of the treatment period. A final MRI was also performed at the end of the 12 month treatment period. Results-There was a significant increase in the mean hyperintense lesion volume during the pretreatment phase (6 months) and a slight decrease during the treatment period (12 months), whereas the hypointense lesion volume increased significantly before treatment and remained substantially stable during treatment. There was a significant correlation between changes in hypointense and hyperintense lesion volume during the observation period, but not during treatment. The monthly mean volume of Gadolinium-DTPA enhancing lesions was significantly higher during the pretreatment than the treatment period, and the enhancing lesion volume correlated with changes of hyperintense and hypointense lesion volumes only during the observation period. Conclusion-These data suggest that interferon-beta-1a has a stabilising effect on T1 weighted hypointense lesion volume.
引用
收藏
页码:579 / 584
页数:6
相关论文
共 31 条
[1]
INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DUQUETTE, P ;
GIRARD, M ;
DESPAULT, L ;
DUBOIS, R ;
KNOBLER, RL ;
LUBLIN, FD ;
KELLEY, L ;
FRANCIS, GS ;
LAPIERRE, Y ;
ANTEL, J ;
FREEDMAN, M ;
HUM, S ;
GREENSTEIN, JI ;
MISHRA, B ;
MULDOON, J ;
WHITAKER, JN ;
EVANS, BK ;
LAYTON, B ;
SIBLEY, WA ;
LAGUNA, J ;
KRIKAWA, J ;
PATY, DW ;
OGER, JJ ;
KASTRUKOFF, LF ;
MOORE, GRW ;
HASHIMOTO, SA ;
MORRISON, W ;
NELSON, J ;
GOODIN, DS ;
MASSA, SM ;
GUTTERIDGE, E ;
ARNASON, BGW ;
NORONHA, A ;
REDER, AT ;
MARTIA, R ;
EBERS, GC ;
RICE, GPA ;
LESAUX, J ;
JOHNSON, KP ;
PANITCH, HS ;
BEVER, CT ;
CONWAY, K ;
WALLENBERG, JC ;
BEDELL, L ;
VANDENNOORT, S ;
WEINSHENKER, B ;
WEISS, W ;
REINGOLD, S ;
PACHNER, A ;
TAYLOR, W .
NEUROLOGY, 1993, 43 (04) :655-661
[2]
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].
Ebers, GC ;
Rice, G ;
Lesaux, J ;
Paty, D ;
Oger, J ;
Li, DKB ;
Beall, S ;
Devonshire, V ;
Hashimoto, S ;
Hooge, J ;
Kastrukoff, L ;
Krieger, C ;
Mezei, M ;
Seland, P ;
Vorobeychi, G ;
Morrison, W ;
Nelson, J ;
Freedman, MS ;
Chrisie, S ;
Nelson, R ;
Rabinovitch, H ;
Freedman, C ;
Hartung, HP ;
Rieckmann, P ;
Archelos, J ;
Jung, S ;
Weilbach, F ;
Flachenecke, P ;
Sauer, J ;
Hommes, O ;
Jongen, P ;
Brouwer, S ;
McLeod, J ;
Pollard, J ;
Ng, R ;
Sandberg-Wollheim, M ;
Källén, K ;
Nilsson, P ;
Ekberg, R ;
Lundgren, A ;
Jadbäck, G ;
Wikström, J ;
Multanen, J ;
Valjakka, M ;
Carton, H ;
Lissoir, F ;
Declerq, I ;
Vieren, M ;
Peeters, E ;
Dubois, B .
LANCET, 1998, 352 (9139) :1498-1504
[3]
QUANTITATIVE BRAIN MRI LESION LOAD PREDICTS THE COURSE OF CLINICALLY ISOLATED SYNDROMES SUGGESTIVE OF MULTIPLE-SCLEROSIS [J].
FILIPPI, M ;
HORSFIELD, MA ;
MORRISSEY, SP ;
MACMANUS, DG ;
RUDGE, P ;
MCDONALD, WI ;
MILLER, DH .
NEUROLOGY, 1994, 44 (04) :635-641
[4]
Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: Relationship to clinical parameters [J].
Gasperini, C ;
Horsfield, MA ;
Thorpe, JW ;
Kidd, D ;
Barker, GJ ;
Tofts, PS ;
MacManus, DG ;
Thompson, AJ ;
Miller, DH ;
McDonald, WI .
JOURNAL OF MAGNETIC RESONANCE IMAGING, 1996, 6 (04) :580-584
[5]
Quantification of MRI lesion load in multiple sclerosis: A comparison of three computer-assisted techniques [J].
Grimaud, J ;
Lai, M ;
Thorpe, J ;
Adeleine, P ;
Wang, L ;
Barker, GJ ;
Plummer, DL ;
Tofts, PS ;
McDonald, WI ;
Miller, DH .
MAGNETIC RESONANCE IMAGING, 1996, 14 (05) :495-505
[6]
CORRELATION OF SPECTROSCOPY AND MAGNETIZATION-TRANSFER IMAGING IN THE EVALUATION OF DEMYELINATING LESIONS AND NORMAL APPEARING WHITE-MATTER IN MULTIPLE-SCLEROSIS [J].
HIEHLE, JF ;
LENKINSKI, RE ;
GROSSMAN, RI ;
DOUSSET, V ;
RAMER, KN ;
SCHNALL, MD ;
COHEN, JA ;
GONZALEZSCARANO, F .
MAGNETIC RESONANCE IN MEDICINE, 1994, 32 (03) :285-293
[7]
Apparent diffusion coefficients in benign and secondary progressive multiple sclerosis by nuclear magnetic resonance [J].
Horsfield, MA ;
Lai, M ;
Webb, SL ;
Barker, GJ ;
Tofts, PS ;
Turner, R ;
Rudge, P ;
Miller, DH .
MAGNETIC RESONANCE IN MEDICINE, 1996, 36 (03) :393-400
[8]
Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].
Jacobs, LD ;
Cookfair, DL ;
Rudick, RA ;
Herndon, RM ;
Richert, JR ;
Salazar, AM ;
Fischer, JS ;
Goodkin, DE ;
Granger, CV ;
Simon, JH ;
Alam, JJ ;
Bartoszak, DM ;
Bourdette, DN ;
Braiman, J ;
Brownscheidle, CM ;
Coats, ME ;
Cohan, SL ;
Dougherty, DS ;
Kinkel, RP ;
Mass, MK ;
Munschauer, FE ;
Priore, RL ;
Pullicino, PM ;
Scherokman, BJ ;
WeinstockGuttman, B ;
Whitman, RH ;
Baird, WC ;
Fillmore, M ;
Bona, LM ;
ColonRuiz, ME ;
Nadine, BS ;
Donovan, A ;
Bennett, S ;
Kieffer, YM ;
Umhauer, MA ;
Miller, CE ;
Kilic, AK ;
Sargent, EL ;
Schachter, M ;
Shucard, DW ;
Weider, V ;
Catalano, BA ;
Cervi, JM ;
Czekay, C ;
Farrell, JL ;
Filippini, JS ;
Matyas, RC ;
Michienzi, KE ;
Ito, M ;
OMalley, JA .
ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294
[9]
Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis [J].
Kappos, L ;
Polman, C ;
Pozzilli, C ;
Thompson, A ;
Dahlke, F ;
Knight, R ;
Hern, J ;
Coleman, R ;
Gerrie, L ;
Cooper, G ;
Moore, J ;
Boringa, J ;
van Oosten, B ;
Ronner, H ;
Schrijver, H ;
Truyen, L ;
Montalbán, J ;
Río, J ;
Tintoré, M ;
Jacas, C ;
Marzo, E ;
Lechner-Scott, J ;
Huber, S ;
Lienert, C ;
Brunnschweiler, H ;
Hawkins, S ;
Droogan, A ;
McDonnell, G ;
Duddy, M ;
McKinstry, S ;
Altenkirch, H ;
Baum, K ;
Einhäupl, K ;
Marx, P ;
Poewe, W ;
Walter, G ;
Akman, H ;
Brockmeier, B ;
Scherer, P ;
Zschenderlein, R ;
Schmierer, K ;
Gelderblom, H ;
Hartmann, A ;
Stapf, C ;
Lüschow, A ;
Mackert, B ;
Schumacher, H ;
Masuhr, F ;
Hempel, T ;
Zimmermann, R .
LANCET, 1998, 352 (9139) :1491-1497
[10]
Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis [J].
Leppert, D ;
Waubant, E ;
Burk, MR ;
Oksenberg, JR ;
Hauser, SL .
ANNALS OF NEUROLOGY, 1996, 40 (06) :846-852